Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × rrCLL × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 74 Melanoma 49 Squamous Cell Carcinoma of Head and Neck 39 Neoplasm Metastasis 28 Neoplasms 26 Breast Neoplasms 24 Carcinoma, Renal Cell 23 Colorectal Neoplasms 22 Head and Neck Neoplasms 21 Carcinoma, Transitional Cell 20 Triple Negative Breast Neoplasms 19 Stomach Neoplasms 19 Ovarian Neoplasms 17 Lung Neoplasms 14 Uterine Cervical Neoplasms 12 Esophageal Neoplasms 12 Carcinoma, Hepatocellular 12 Urinary Bladder Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Pancreatic Neoplasms 10 Small Cell Lung Carcinoma 9 Multiple Myeloma 9 Recurrence 8 Endometrial Neoplasms 8 Carcinoma, Merkel Cell 8 Lymphoma, Non-Hodgkin 7 Lymphoma 7 Mesothelioma 6 Hodgkin Disease 6 Fallopian Tube Neoplasms 6

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡